Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Katrina S, Pedersen"'
Autor:
Scott McHenry, Xiaoyu Zong, Mengyao Shi, Cassandra D.L Fritz, Katrina S. Pedersen, Linda R. Peterson, Jeffrey K. Lee, Ryan C. Fields, Nicholas O. Davidson, Yin Cao
Publikováno v:
Hepatology Communications, Vol 6, Iss 12, Pp 3299-3310 (2022)
Abstract Metabolic syndrome may contribute to the rising incidence of multiple gastrointestinal (GI) cancers in recent birth cohorts. However, other than hepatocellular carcinoma, the association between nonalcoholic fatty liver disease (NAFLD) and r
Externí odkaz:
https://doaj.org/article/f0990c9029754d4b95c0a0a689937c90
Autor:
Semra Ince, Malak Itani, Lauren E. Henke, Radhika K. Smith, Paul E. Wise, Matthew G. Mutch, Sean C. Glasgow, Matthew L. Silviera, Katrina S. Pedersen, Steven R. Hunt, Hyun Kim, Tyler J. Fraum
Publikováno v:
Tomography, Vol 8, Iss 6, Pp 2723-2734 (2022)
Nonoperative management (NOM) is increasingly utilized for rectal cancer patients with a clinical complete response (cCR) following total neoadjuvant therapy (TNT). The objective of this pilot study was to determine whether FDG-PET/MRI alters clinica
Externí odkaz:
https://doaj.org/article/adda103426fe4eef80e6443495e1346a
Autor:
Chen Li, Ana Ferro, Shivani K. Mhatre, Danny Lu, Marcus Lawrance, Xiao Li, Shi Li, Simon Allen, Jayesh Desai, Marwan Fakih, Michael Cecchini, Katrina S. Pedersen, Tae You Kim, Irmarie Reyes-Rivera, Neil H. Segal, Christelle Lenain
Publikováno v:
Communications Medicine, Vol 2, Iss 1, Pp 1-8 (2022)
Li et al. report outcomes from the atezolizumab/isatuximab arm of the phase Ib/II MORPHEUS-CRC trial in patients with metastatic colorectal cancer. In addition, the authors leverage historical control data from the phase III IMblaze370 study to provi
Externí odkaz:
https://doaj.org/article/a2d8a6d7f97440f4b6e89b19aac1153c
Autor:
Hyun Kim, MD, Amar Srivastava, MD, Prashant Gabani, MD, Elizabeth Kim, MD, Hohyun Lee, Katrina S. Pedersen, MD
Publikováno v:
Advances in Radiation Oncology, Vol 7, Iss 2, Pp 100861- (2022)
Purpose: The medical trainee perspective regarding the prior authorization process has not been previously assessed. Here we evaluate the perceptions of radiation and medical oncology trainees regarding the prior authorization process and its effect
Externí odkaz:
https://doaj.org/article/74a33712531b47808ec610ab841c42cb
Autor:
Patrick M Grierson, Benjamin Tan, Katrina S Pedersen, Haeseong Park, Rama Suresh, Manik A Amin, Nikolaos A Trikalinos, Deborah Knoerzer, Brent Kreider, Anupama Reddy, Jingxia Liu, Channing J Der, Andrea Wang-Gillam, Kian-Huat Lim
Publikováno v:
The Oncologist. 28:e115-e123
Background Ulixertinib is a novel oral ERK inhibitor that has shown promising single-agent activity in a phase I clinical trial that included patients with RAS-mutant cancers. Methods We conducted a phase Ib trial combining ulixertinib with gemcitabi
Autor:
Jonathan W. Goldman, Sarina A. Piha-Paul, Brendan Curti, Katrina S. Pedersen, Todd M. Bauer, Stefanie L. Groenland, Richard D. Carvajal, Vaishali Chhaya, Gray Kirby, Kelly McGlinchey, Scott A. Hammond, Katie Streicher, Danielle M. Townsley, Young Kwang Chae, Jens Voortman, Aurelien Marabelle, John Powderly
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, 28(17), 3709-3719. American Association for Cancer Research Inc.
Goldman, J W, Piha-Paul, S A, Curti, B, Pedersen, K S, Bauer, T M, Groenland, S L, Carvajal, R D, Chhaya, V, Kirby, G, McGlinchey, K, Hammond, S A, Streicher, K, Townsley, D M, Chae, Y K, Voortman, J, Marabelle, A & Powderly, J 2022, ' Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 28, no. 17, pp. 3709-3719 . https://doi.org/10.1158/1078-0432.CCR-21-3016
Goldman, J W, Piha-Paul, S A, Curti, B, Pedersen, K S, Bauer, T M, Groenland, S L, Carvajal, R D, Chhaya, V, Kirby, G, McGlinchey, K, Hammond, S A, Streicher, K, Townsley, D M, Chae, Y K, Voortman, J, Marabelle, A & Powderly, J 2022, ' Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 28, no. 17, pp. 3709-3719 . https://doi.org/10.1158/1078-0432.CCR-21-3016
Purpose: Combination therapies targeting immunologic checkpoints have shown promise in treating multiple tumor types. We report safety and tolerability of MEDI0562, a humanized IgG1K OX40 mAb, in combination with durvalumab (anti-PD-L1), or tremelimu
Autor:
Robert R. McWilliams, Richard H. Wilson, Jack Welch, Rondell P. Graham, Tanios Bekaii-Saab, Brandy L. Jaszewski, Kathryn A. Arrambide, Sunnie S. Kim, Patrick M. Boland, Michael J. Overman, Nathan R. Foster, Katrina S. Pedersen
Revised supplemental figures and tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c040166ba1f157e501dc8a4975a1585
https://doi.org/10.1158/1078-0432.22481196.v1
https://doi.org/10.1158/1078-0432.22481196.v1
Autor:
Robert R. McWilliams, Richard H. Wilson, Jack Welch, Rondell P. Graham, Tanios Bekaii-Saab, Brandy L. Jaszewski, Kathryn A. Arrambide, Sunnie S. Kim, Patrick M. Boland, Michael J. Overman, Nathan R. Foster, Katrina S. Pedersen
Purpose:Small-bowel adenocarcinoma (SBA) is rare, and no standard of care exists for metastatic disease beyond first-line FOLFOX/CAPOX. SBA has higher rates of microsatellite instability (MSI-H) and T-lymphocyte infiltration than other gastrointestin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9307ecdbee6931a790a7cd2888742fdb
https://doi.org/10.1158/1078-0432.c.6530637.v1
https://doi.org/10.1158/1078-0432.c.6530637.v1
Autor:
John Powderly, Aurelien Marabelle, Jens Voortman, Young Kwang Chae, Danielle M. Townsley, Katie Streicher, Scott A. Hammond, Kelly McGlinchey, Gray Kirby, Vaishali Chhaya, Richard D. Carvajal, Stefanie L. Groenland, Todd M. Bauer, Katrina S. Pedersen, Brendan Curti, Sarina A. Piha-Paul, Jonathan W. Goldman
Purpose:Combination therapies targeting immunologic checkpoints have shown promise in treating multiple tumor types. We report safety and tolerability of MEDI0562, a humanized IgG1K OX40 mAb, in combination with durvalumab (anti-PD-L1), or tremelimum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ad56ad0b2823ff924e7b6b8318b470e
https://doi.org/10.1158/1078-0432.c.6532478
https://doi.org/10.1158/1078-0432.c.6532478
Autor:
John Powderly, Aurelien Marabelle, Jens Voortman, Young Kwang Chae, Danielle M. Townsley, Katie Streicher, Scott A. Hammond, Kelly McGlinchey, Gray Kirby, Vaishali Chhaya, Richard D. Carvajal, Stefanie L. Groenland, Todd M. Bauer, Katrina S. Pedersen, Brendan Curti, Sarina A. Piha-Paul, Jonathan W. Goldman
Supplementary Figure from Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a03147e35ccf0f48c28148c327500f9
https://doi.org/10.1158/1078-0432.22487267.v1
https://doi.org/10.1158/1078-0432.22487267.v1